Simonett JM, Skalet AH, Lujan BJ, et al. - Researchers conducted this retrospective case series to investigate the rate of and risk factors for the development of blood-brain barrier disruption (BBBD)-associated maculopathy and to evaluate whether there can be visually significant progression after completion of systemic therapy. Sixty-eight (mean [SD] age, 46.0 [17.9] years; 25 [38.5%] female) of the 283 patients treated with BBBD and chemotherapy for the central nervous system (CNS) malignant neoplasm had an ophthalmic examination after beginning systemic therapy. The number of BBBD treatment sessions, but not age, CNS malignant cancer type, or systemic chemotherapy agent, was linked to maculopathy development. An association was observed between BBBD-related maculopathy and the number of BBBD treatment sessions, indicating a dose-dependent effect. In some cases, the progression of maculopathy, including an increase in geographic atrophy, occurred years after the completion of systemic therapy. Such results may have major consequences for the education of patients and ophthalmic monitoring.